Cargando…

Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study

BACKGROUND: There were few related studies aiming to severe IgA nephropathy (IgAN) which could progress rapidly to end stage renal disease (ESRD) within ten years. To find valuable clinical or pathological factors and promising precautions is essential. METHODS: A single center case–control study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Danhua, Xu, Feifei, Su, Zhen, Zhang, Ji, Chen, Chaosheng, Zhang, Jianna, Ding, Xiaokai, Lv, Yinqiu, Lin, Haixia, Huang, Peipei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219698/
https://www.ncbi.nlm.nih.gov/pubmed/28061828
http://dx.doi.org/10.1186/s12882-016-0429-x
_version_ 1782492504546869248
author Shu, Danhua
Xu, Feifei
Su, Zhen
Zhang, Ji
Chen, Chaosheng
Zhang, Jianna
Ding, Xiaokai
Lv, Yinqiu
Lin, Haixia
Huang, Peipei
author_facet Shu, Danhua
Xu, Feifei
Su, Zhen
Zhang, Ji
Chen, Chaosheng
Zhang, Jianna
Ding, Xiaokai
Lv, Yinqiu
Lin, Haixia
Huang, Peipei
author_sort Shu, Danhua
collection PubMed
description BACKGROUND: There were few related studies aiming to severe IgA nephropathy (IgAN) which could progress rapidly to end stage renal disease (ESRD) within ten years. To find valuable clinical or pathological factors and promising precautions is essential. METHODS: A single center case–control study was performed. Fifty ESRD patients with the primary cause of IgAN and a short renal survival time of less than ten years after diagnose were enrolled in the case group. One hundred IgAN patients with a renal survival time of more than ten years were enrolled in the control group. IgA Oxford classification scores, clinical data at baseline and during the follow-up were collected. Multivariate logistic regression was used to investigate factors associated with the development of ESRD. RESULTS: There were significant differences in baseline clinical data between these two groups, as well as the constituent ratio of Oxford MEST-score. Distinct differences were observed in time-average uric acid(TA-UA), time-average hemoglobin(TA-Hb), time-average albumin(TA-Alb), time-average total cholesterol(TA-TC) and time-average urinary protein(TA-P) during the follow-up. In multivariate logistic models, IgA Oxford score M1(OR = 5.10, P = 0.018) and eGFR(OR = 0.97, P = 0.039) at biopsy, TA-UA (OR = 2.06, P = 0.026) and TA-Hb (OR = 0.53, P = 0.022) during the follow-up were identified independent factors for developing ESRD. CONCLUSION: IgAN patients with pathological assessment of M1, low baseline eGFR, TA-Hb and high TA-UA were more likely to progress to ESRD, and should be paid more attention. Appropriate regulations of UA, Hb and urine protein after diagnose may be a promising treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-016-0429-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5219698
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52196982017-01-10 Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study Shu, Danhua Xu, Feifei Su, Zhen Zhang, Ji Chen, Chaosheng Zhang, Jianna Ding, Xiaokai Lv, Yinqiu Lin, Haixia Huang, Peipei BMC Nephrol Research Article BACKGROUND: There were few related studies aiming to severe IgA nephropathy (IgAN) which could progress rapidly to end stage renal disease (ESRD) within ten years. To find valuable clinical or pathological factors and promising precautions is essential. METHODS: A single center case–control study was performed. Fifty ESRD patients with the primary cause of IgAN and a short renal survival time of less than ten years after diagnose were enrolled in the case group. One hundred IgAN patients with a renal survival time of more than ten years were enrolled in the control group. IgA Oxford classification scores, clinical data at baseline and during the follow-up were collected. Multivariate logistic regression was used to investigate factors associated with the development of ESRD. RESULTS: There were significant differences in baseline clinical data between these two groups, as well as the constituent ratio of Oxford MEST-score. Distinct differences were observed in time-average uric acid(TA-UA), time-average hemoglobin(TA-Hb), time-average albumin(TA-Alb), time-average total cholesterol(TA-TC) and time-average urinary protein(TA-P) during the follow-up. In multivariate logistic models, IgA Oxford score M1(OR = 5.10, P = 0.018) and eGFR(OR = 0.97, P = 0.039) at biopsy, TA-UA (OR = 2.06, P = 0.026) and TA-Hb (OR = 0.53, P = 0.022) during the follow-up were identified independent factors for developing ESRD. CONCLUSION: IgAN patients with pathological assessment of M1, low baseline eGFR, TA-Hb and high TA-UA were more likely to progress to ESRD, and should be paid more attention. Appropriate regulations of UA, Hb and urine protein after diagnose may be a promising treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-016-0429-x) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-07 /pmc/articles/PMC5219698/ /pubmed/28061828 http://dx.doi.org/10.1186/s12882-016-0429-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Shu, Danhua
Xu, Feifei
Su, Zhen
Zhang, Ji
Chen, Chaosheng
Zhang, Jianna
Ding, Xiaokai
Lv, Yinqiu
Lin, Haixia
Huang, Peipei
Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study
title Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study
title_full Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study
title_fullStr Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study
title_full_unstemmed Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study
title_short Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study
title_sort risk factors of progressive iga nephropathy which progress to end stage renal disease within ten years: a case–control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219698/
https://www.ncbi.nlm.nih.gov/pubmed/28061828
http://dx.doi.org/10.1186/s12882-016-0429-x
work_keys_str_mv AT shudanhua riskfactorsofprogressiveiganephropathywhichprogresstoendstagerenaldiseasewithintenyearsacasecontrolstudy
AT xufeifei riskfactorsofprogressiveiganephropathywhichprogresstoendstagerenaldiseasewithintenyearsacasecontrolstudy
AT suzhen riskfactorsofprogressiveiganephropathywhichprogresstoendstagerenaldiseasewithintenyearsacasecontrolstudy
AT zhangji riskfactorsofprogressiveiganephropathywhichprogresstoendstagerenaldiseasewithintenyearsacasecontrolstudy
AT chenchaosheng riskfactorsofprogressiveiganephropathywhichprogresstoendstagerenaldiseasewithintenyearsacasecontrolstudy
AT zhangjianna riskfactorsofprogressiveiganephropathywhichprogresstoendstagerenaldiseasewithintenyearsacasecontrolstudy
AT dingxiaokai riskfactorsofprogressiveiganephropathywhichprogresstoendstagerenaldiseasewithintenyearsacasecontrolstudy
AT lvyinqiu riskfactorsofprogressiveiganephropathywhichprogresstoendstagerenaldiseasewithintenyearsacasecontrolstudy
AT linhaixia riskfactorsofprogressiveiganephropathywhichprogresstoendstagerenaldiseasewithintenyearsacasecontrolstudy
AT huangpeipei riskfactorsofprogressiveiganephropathywhichprogresstoendstagerenaldiseasewithintenyearsacasecontrolstudy